Özet:

OBJECTIVE: To assess the mutation status of the patients with Chronic Myeloid Leukemia (CML) who have been treated and followed-up in our clinics and to assess the response to the treatments.METHODS: All the patients with the diagnosis of CML (n:100) were invited, 6 patients who could not be reached and 2 patients who did not want to participate were excluded. The data were gathered from files and from patient examinations. The most common 5 mutations - T315I, Y253H, E255K, E255V and M351T mutations - were assessed. Interferon-alpha, imatinib, nilotinib and dasatinib were given as first, second and third line therapies where appropriate. The disease phases, hematologic and major molecular responses, commencement time for response, new drug requirements and adverse effects were evaluated. The association between the presence of mutations and rate of the major molecular response were analyzed.RESULTS: The prevalence of the mutations in the studied population was found to be 3.3%. T315I mutation was detected in 2 patients and no response could be obtained with either nilotinib or dasatinib in these two patients. These patients were still in the accelerated phase. In one patient with M351T mutation major molecular response could not be obtained with these two drugs. Among ABL kinase domain mutations presence of T315I mutation is associated with the highest degree of resistance to imatinib, dasatinib and nilotinib. CONCLUSION: In this study it was found that presence of mutations may affect the rate of major molecular response negatively.

Anahtar Kelimeler: